Welcome to Edition 8.44 of the Rocket Report! The news this week is decidedly weighted in favor of heavy-lift rockets, largely due to the fallout from last Thursday’s explosion of Blue Origin’s New ...

Blue Origin is planning to fly its New Glenn rocket again in 2026 despite last week’s massive explosion, according to CEO Dave Limp. Limp said Monday that more of the launchpad’s infrastructure was in ...

The chief executive of Blue Origin, whose large New Glenn rocket exploded spectacularly less than a week ago at the company’s launch site in Florida, vowed Monday night that the company would launch ...

Blue Origin's New Glenn rocket has exploded on its launchpad at Cape Canaveral Space Force Station while the company was conducting ground tests for an upcoming launch. The company explained that it ...

Blue Origin’s New Glenn mega-rocket just exploded during testing at a launch site in Cape Canaveral, Florida, according to livestreams from NASASpaceFlight.com and SpaceFlight Now. Blue Origin later ...

ALLENTOWN, Pa. - From a street sketch by Walter Baum, to a Salubrious summer scene, to stuffed and or oiled poultry, to Percussive pottery. They’re all part of the 500 pieces making up the Baum School ...

Personalized algorithms may quietly sabotage how people learn, nudging them into narrow tunnels of information even when they start with zero prior knowledge. In the study, participants using ...

Tre Welch is known for his hilarious comedy videos online, which often feature his mother, Lorenda, and her best friend, Shelly Tabitha Parent is a writer at PEOPLE covering entertainment and culture.

Pfizer’s chief strategist, Andrew Baum, M.D., is leaving his post two years after pivoting from a career-long tenure as a biopharma equity research analyst to join the New York drugmaker. Baum is ...

April 20 (Reuters) - Pfizer's (PFE.N), opens new tab Chief Strategy and Innovation Officer, Andrew Baum, is transitioning to a new role and will eventually leave the ‌company as part of the U.S.

Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast ...